The Comprehensive Cancer Center
at Our Lady of Mercy Medical Center in the Bronx, New York today announced
positive results from a pivotal Phase II trial of REVLIMID in patients with
relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). Final results
showed that 67 percent of patients, who had received a prior stem cell
transplant, and 45 percent of patients, who have had one to two prior
treatment regimens, achieved objective responses within a median time of
two months with REVLIMID. Additionally, study results showed a 59 percent
tumor control rate in patients.
NHL is the most common form of blood cancer in the United States
affecting more than 360,000 people. Approximately 50 percent have
aggressive NHL, while the other half have indolent or follicular lymphoma.
According to the American Cancer Society, more than 56,000 men and women in
the United States are diagnosed with NHL each year, and 19,000 are expected
to die from NHL in 2006.
"These data are very promising for the non-Hodgkin's lymphoma community
in that more treatment options are showing benefits for patients," says
Peter H. Wiernik, MD, Professor of Medicine at the New York Medical College
and the Director of the Comprehensive Cancer Center at Our Lady of Mercy
Medical Center, and the study's lead investigator. "Rather than taking
combination medications to treat NHL, these results show that taking a
single oral pill like REVLIMID can be enough to produce favorable
responses."
The study, sponsored by Celgene, enrolled 32 patients. In addition to
achieving significant objective responses, only 13 percent experienced a
Grade 4 adverse reaction.
REVLIMID is indicated for use as a treatment in combination with
dexamethasone for multiple myeloma patients who have received at least one
prior therapy. REVLIMID is also indicated for treatment of patients with
transfusion-dependent anemia due to Low- or Intermediate-1-risk
myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic
abnormality with or without additional cytogenetic abnormalities.
About The Comprehensive Cancer Center at Our Lady of Mercy Medical
Center
The Comprehensive Cancer Center at Our Lady of Mercy Medical Center
offers a wide range of opportunities for cancer patients in the region.
This "Center of Excellence" combines the latest advances in the treatment
and care of cancer patients with research facilities dedicated to advancing
the understanding of cancer and improving treatment modalities. Visit our
website at olmcancer
About Our Lady of Mercy Medical Center
The Our Lady of Mercy Medical Center is a University Hospital of New
York Medical College and a member of the Montefiore Health System. Visit
our website at olmhs.
Our Lady of Mercy Medical Center
olmhs
View drug information on Revlimid.